Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | MGLL | Q99685 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8243508 | 0.79 | — | — | |
| SCHEMBL23500950 | 0.77 | — | — | |
| SCHEMBL15846673 | 0.74 | FAAH (0.45) | FAAHMGLLALDH1A1LMNAMAPT | |
| SCHEMBL1325 | 0.74 | FAAH (0.45) | FAAHMGLLALDH1A1LMNAMAPT | |
| SCHEMBL10814524 | 0.72 | FAAH (0.44) | FAAHMGLLALDH1A1LMNAMAPT | |
| Hydrogen Sulfide SCHEMBL10814521 | 0.72 | FAAH (0.44) | FAAHMGLLALDH1A1LMNAMAPT | |
| Phosphine SCHEMBL31680518 | 0.72 | FAAH (0.44) | FAAHMGLLALDH1A1LMNAMAPT | |
| SCHEMBL2194853 | 0.72 | FAAH (0.44) | FAAHMGLLALDH1A1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL6226784 | 0.72 | FAAH (0.44) | FAAHMGLLALDH1A1LMNAMAPT | |
| SCHEMBL30730242 | 0.71 | FAAH (0.55) | FAAHMGLLALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822327-B2 | Perfume systems | THE PROCTER & GAMBLE COMPANY (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160186093-A1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2016-06-30 | — | — | US | disclosed |
| US-8324244-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8293753-B2 | Substituted 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8133884-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-13 | — | — | US | disclosed |
| US-8039483-B2 | Quinuclidine carbonate salts and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-10-18 | — | — | US | disclosed |
| US-20110160458-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110105473-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-05-05 | — | — | US | disclosed |
| US-7935716-B2 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20110015367-A1 | UNSATURATED POLY(ESTER-AMIDE) AND POLY(ETHER ESTER AMIDE) BIOMATERIALS | CORNELL UNIVERSITY (US) | 2011-01-20 | — | — | US | disclosed |
| US-20090076063-A1 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090048229-A1 | Methods for promoting wakefulness | COLUCID PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| EP-1905829-A2 | Templated molecules and methods for using such molecules | Nuevolution A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| US-20070275959-A1 | Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents | SENTION, INC. | 2007-11-29 | — | — | US | disclosed |
| EP-1440797-B1 | Heat-sensitive lithographic printing plate precursor | AGFA GRAPHICS NV (BE) | 2007-10-03 | — | — | EP | disclosed |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2007-06-21 | — | — | US | disclosed |
| WO-2007062177-A2 | MOLECULAR CONJUGATE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20060276482-A1 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists | THERAVANCE, INC. | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276482-A1 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists | HTR4, HTR5A, HTR1A | FAAH 213/4885MGLL 2553/4885ALDH1A1 2503/4885 |
| US-20110105473-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | IDO1, HCCS, CCNI | FAAH 3323/4885MGLL 2646/4885ALDH1A1 1275/4885 |
| US-20090076063-A1 | Carboxamide compound and use of the same | CBR3, SIRT2, SIRT1 | FAAH 155/4885MGLL 3497/4885ALDH1A1 3016/4885 |
| US-20070275959-A1 | Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents | ACHE, BCHE, CHAT | FAAH 67/4885MGLL 98/4885ALDH1A1 918/4885 |
| US-20090048229-A1 | Methods for promoting wakefulness | HCRTR2, HCRTR1, CHAT | FAAH 41/4885MGLL 580/4885ALDH1A1 3038/4885 |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | PNLIP, IAPP, GPR119 | FAAH 2753/4885MGLL 44/4885ALDH1A1 1567/4885 |
| US-20110160458-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | FAAH 4073/4885MGLL 3229/4885ALDH1A1 2138/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | FAAH 3463/4885MGLL 1750/4885ALDH1A1 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.